Home › Diffuse Large B-Cell Lymphoma › Kansas
Diffuse Large B-Cell Lymphoma clinical trials in Kansas
7 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in Kansas.
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Cotton O'Neil Cancer Center ( Site 0108), Topeka
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06717347A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Kansas Cancer Center, Kansas City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- University of Kansas Cancer Center, Westwood
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Kansas Cancer Center, Westwood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- University of Kansas Cancer Center, Westwood
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489SynKIR-310 for Relapsed/Refractory B-NHL
- The University of Kansas Cancer Center, Fairway
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT06544265Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- University of Kansas Cancer Center, Kansas City
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Westwood Cancer Center, Westwood
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 2, 2026 · NCT05633615From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.